CA3110346A1 - Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses - Google Patents

Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses Download PDF

Info

Publication number
CA3110346A1
CA3110346A1 CA3110346A CA3110346A CA3110346A1 CA 3110346 A1 CA3110346 A1 CA 3110346A1 CA 3110346 A CA3110346 A CA 3110346A CA 3110346 A CA3110346 A CA 3110346A CA 3110346 A1 CA3110346 A1 CA 3110346A1
Authority
CA
Canada
Prior art keywords
subject
diabetes
ezetimibe
fixed dose
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3110346A
Other languages
English (en)
French (fr)
Inventor
Narendra Dhanraj Lalwani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esperion Therapeutics Inc
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69591419&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3110346(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of CA3110346A1 publication Critical patent/CA3110346A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3110346A 2018-08-24 2019-08-26 Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses Pending CA3110346A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862722766P 2018-08-24 2018-08-24
US62/722,766 2018-08-24
US201862751404P 2018-10-26 2018-10-26
US62/751,404 2018-10-26
PCT/US2019/048184 WO2020041799A1 (en) 2018-08-24 2019-08-26 Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses

Publications (1)

Publication Number Publication Date
CA3110346A1 true CA3110346A1 (en) 2020-02-27

Family

ID=69591419

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3110346A Pending CA3110346A1 (en) 2018-08-24 2019-08-26 Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses

Country Status (15)

Country Link
US (1) US20210322376A1 (https=)
EP (1) EP3841105A4 (https=)
JP (2) JP2021534208A (https=)
KR (1) KR20210079275A (https=)
CN (1) CN113166195A (https=)
AU (1) AU2019325705A1 (https=)
BR (1) BR112021003265A2 (https=)
CA (1) CA3110346A1 (https=)
CL (1) CL2021000444A1 (https=)
CO (1) CO2021003726A2 (https=)
IL (1) IL281016A (https=)
MX (1) MX2021002090A (https=)
PH (1) PH12021550656A1 (https=)
SG (1) SG11202101717WA (https=)
WO (1) WO2020041799A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3267989A4 (en) 2015-03-13 2018-11-07 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
US20210322375A1 (en) * 2018-08-27 2021-10-21 Esperion Therapeutics, Inc. Combination drug formulations for treating patients with cardiovascular disease and associated conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008000684A1 (es) * 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN103239449A (zh) * 2012-12-26 2013-08-14 辽宁亿灵科创生物医药科技有限公司 一种依折麦布、辛伐他汀和烟酸的复方制剂及其制备方法
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2018148417A1 (en) * 2017-02-08 2018-08-16 Esperion Therapeutics, Inc. Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease

Also Published As

Publication number Publication date
SG11202101717WA (en) 2021-03-30
CN113166195A (zh) 2021-07-23
CO2021003726A2 (es) 2021-07-30
CL2021000444A1 (es) 2021-07-02
MX2021002090A (es) 2021-04-28
WO2020041799A1 (en) 2020-02-27
KR20210079275A (ko) 2021-06-29
BR112021003265A2 (pt) 2021-05-18
PH12021550656A1 (en) 2022-03-14
EP3841105A1 (en) 2021-06-30
JP2024081650A (ja) 2024-06-18
US20210322376A1 (en) 2021-10-21
IL281016A (en) 2021-04-29
JP2021534208A (ja) 2021-12-09
EP3841105A4 (en) 2022-05-04
AU2019325705A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
US20250064767A1 (en) Fixed dose combinations and formulations comprising etc1002 and one or more statins and methods of treating or reducing the risk of cardiovascular disease
US20240398746A1 (en) Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
EP4461295A2 (en) Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
JP2024081650A (ja) 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法
TW200306853A (en) Therapeutic agent for glomerular disease
US20210322375A1 (en) Combination drug formulations for treating patients with cardiovascular disease and associated conditions
HK40107190A (en) Fixed dose combinations and formulations comprising etc1002 and one or more statins and methods of treating or reducing the risk of cardiovascular disease
KR20250034041A (ko) 혈중 ldl 콜레스테롤 저하제
HK40118219A (en) Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
HK1245643B (en) Fixed dose combinations comprising etc1002 and one or more statins for treating or reducing cardiovascular risk

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220924